US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410

26 Apr 2023
www.pharmaceutical-technology.com
ImmunotherapyOrphan DrugCell TherapyPhase 2
US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410
Preview
Source: Pharmaceutical Technology
Hasini Devarasetti
US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410
Preview
Source: Pharmaceutical Technology
IN8bio’s INB-400 and INB-410 are indicated to treat newly diagnosed glioblastoma multiforme. Credit: Nephron/ commons.wikimedia.org.
The US Food and Drug Administration (FDA) has granted orphan drug designation to IN8bio’s INB-400 and INB-410 to treat a range of malignant gliomas, including newly diagnosed glioblastoma multiforme (GBM).
This marks the first-ever designation for genetically modified gamma-delta T cell therapies.
Recommended Reports
US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - LXE-408 in Chagas Disease (American Trypanosomiasis) GlobalData
US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Cariprazine in Autism Spectrum Disorder (ASD) GlobalData
View all
INB-400, an autologous, genetically engineered gamma-delta T cell therapy, is the company’s DeltEx chemotherapy-resistant autologous and allogeneic drug-resistant immunotherapy (DRI) technology.
It will expand the application of DRI gamma-delta T cells into other solid tumour types by developing allogeneic or “off-the-shelf” DeltEx DRI technology.
The regulator cleared the company’s investigational new drug (IND) application to commence a Phase II clinical trial of INB-400 in newly diagnosed GBM in December 2022.
The trial has been designed to evaluate the tolerability, efficacy and safety of genetically modified DeltEx DRI cells at medical centres across the US.
Participant enrolment is anticipated to commence in the second half of 2023.
The Institutional Review Board’s (IRB) review and site initiation are ongoing.
IN8bio CEO and co-founder William Ho stated: “Our goal is to achieve our ‘mission of cancer zero’ by eradicating cancer cells and improving patient outcomes.
“Our novel approach combines engineered, chemo-resistant, gamma-delta T cells with standard-of-care treatments to amplify immune signals, maximise tumour killing and eliminate more cancer cells. We eagerly anticipate enrolling our first Phase II patients for INB-400 later this year.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.